Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-03-13
1999-09-21
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546200, A61K 31445, C07D40104
Patent
active
059554762
ABSTRACT:
1-Oxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindolines and 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidin-3-yl)isoindolines reduce the levels of inflammatory cytokines such as TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidin-3 -yl)-isoindoline.
REFERENCES:
patent: 5593990 (1997-01-01), D'Amato
patent: 5874448 (1999-02-01), Muller et al.
Haslett, et al., "Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8 + Subset", J.Exp.Med., vol. 187, No. 11: 1885-1892 (Jun. 1, 1998).
Teubert, et al., "5'-Substituted Thalidomide Analogs as Modulators of TNF-.alpha.*" Arch. Pharm. Pharm. Med. Chem., 331: 7-12 (1998).
Niwayama, et al., "Enhanced Potency of Perfluorinated Thalidomide Derivatives for Inhibition of LPS-Induced Tumor Necrosis Factor-.alpha.-Production is Associated with a Change of Mechanism of Action" Bioorganic & Medicinal Chemistry Letters, 8: 1071-1076 (1998).
Miyachi, et al., "Tumor Necrosis Factor-Alpha Production Enhancing Activity of Substituted 3'-Methylthalidomide: Influence of Substituents at the Phthaloyl Moiety on the Activity and Stereoselectivity", Chem. Pharm. Bull., 46(7): 1165-1168 (1998).
Hashimoto, et al., "Novel Biological Response Modifiers Derived from Thalidomide", Current Medicinal Chemistry, 5: 163-178 (1998).
Miyachi, et al., "Tumor Necrosis Factor-alpha Production-inhibiting Activity of Phthalimide Analogues on Human Leukemia THP-1 Cells and a Structure-Activity Relationship Study" Bioorganic & Medicinal Chemistry, vol. 5, No. 11: 2095-2102 (1997).
Calderon, et al., "Thalidomide in Dermatology. New Indications for an Old Drug" International Journal of Dermatology, 36: 881-887 (1997).
Jacobson, et al., "Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection" The New England Journal of Medicine, 336: 1487-1493 (1997).
Erikkson, et al., "Enantiomers of Thalidomide: Blood Distribution and the Influence of Serum Albumin on Chiral Inversion and Hydrolysis" Chiralty 10:223-228 (1998).
Moreira, et al., "Thalidomide and Thalidomide Analogs Reduce HIV Type 1 Replication in Human Macrophages in Vitro" Aids Research and Human Retroviruses vol. 13, No. 10: 857-863 (1997).
Miyachi, et al., "Novel Biological Response Modifiers: Phthalimides with Tumor Necrosis Factor-.alpha. Production-Regulating Activity", J. Med. Chem. 40: 2858-2865 (1997).
Tseng, et al., "Rediscovering Thalidomide: A Review of its Mechamism of Action, Side Effects and Potential Uses" Journal of the American Academy of Dermatology vol. 35, No. 6: 969-979 (1996).
Stirling, David I., "Thalidomide: A Pharmaceutical Enigma" Pharmaceutical News, vol. 3, No. 3: 17-20 (1996).
Wnendt, et al., "Enantioselective Inhibition of TNF-.alpha. Release by Thalidomide and Thalidomide Analogues" Chirality 8: 390-396 (1996).
Klausner, et al., "The Effect of Thalidomide on the Pathogenesis of Human Immunodeficiency Virus Type 1 and M. tuberculosis Infection" Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 11: 247-257 (1996).
Corral, et al., "Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor a Inhibitory Activity" Molecular Medicine vol. 2, No. 4: 506-515 (1996).
Zwingenberger, et al., "Immunomodulation by Thalidomide: Systematic Review of the Literature and of Unpublished Observations" Journal of Inflammation 46: 177-211 (1996).
Shannon, et al., "Hydrolysis of Thalidomide Abrogates its Ability to Enhance Mononuclear Cell Synthesis of IL-2 as Well as Its Ability to Suppress the Synthesis of TNF-.alpha." Immunopharmacology 36: 9-15 (1997).
Abo-Sier, et al., "Synthesis of Some 3.4.5-Trimethoxybenzyl Derivatives of Certain Amino Compounds Likely to Possess CNS Activity" Pharmazie 32: 149 (1977).
Miyachi, et al., "Enantio-Dependence of Inducer-Specific Bidirectional Regulation of Tumor Necrosis Factor (TNF)-Alpha Production: Potent TNF-.alpha. Production Inhibitors" Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 19: 2293-2298 (1996).
Stirling, David, "Potential Use of Thalidomide in HIV/AIDS" Annual Reports in Medicinal Chemistry 30: 319-327 (1995).
D'Arcy, et al., "Thalidomide Revisited" Adverse Drug React. Toxicol. Rev. 13(2): 65-76 (1994).
Winter, W., "Thalidomide Enantiomers" The Lancet vol. 339: 365 (Feb. 8, 1992).
Moreira, et al., "Thalidomide Exerts Its Inhibitory Action on Tumor Necrosis Factor .alpha. by Enhancing mRNA Degradation" J. Exp. Med. vol. 177: 1675-1680 (Jun. 1993).
Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor .alpha. Production by Stimulated Human Monocytes" J. Exp. Med. vol. 173: 699-703 (Mar. 1991).
Koch, H.P., "Thalidomide and Congeners as Anti-inflammatory Agents" Progress in Medicinal Chemistry vol. 22: 166-241 (1985).
Chen Roger Shen-Chu
Man Hon-Wah
Muller George W.
Stirling David I.
Celgene Corporation
Rao Deepak R.
Raymond Richard L.
LandOfFree
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-80549